The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Combined modality therapy for early-stage Hodgkin lymphoma in the PET era: A real-world study.
 
Karan Chohan
No Relationships to Disclose
 
Jason R. Young
Stock and Other Ownership Interests - Accelerate Diagnostics; Applied DNA Sciences; crispr therapeutics; Cryoport; Cryoport; Evogene; Fluidigm; Globus Medical; Misonix; Optimizerx; Streamline Health
 
Scott Lester
No Relationships to Disclose
 
Muhamad Alhaj Moustafa
Consulting or Advisory Role - Acrotech Biopharma (Inst); CSL Behring
 
Allison Claire Rosenthal
No Relationships to Disclose
 
Han W. Tun
Honoraria - ADC Therapeutics; Gossamer Bio
Consulting or Advisory Role - Gossamer Bio
Research Funding - Acrotech Biopharma (Inst); Curis (Inst); DTRM (Inst)
Travel, Accommodations, Expenses - Acrotech Biopharma
 
Bradford Hoppe
Consulting or Advisory Role - Merck (Inst)
 
Patrick B. Johnston
No Relationships to Disclose
 
Ivana N. M. Micallef
No Relationships to Disclose
 
Thomas Matthew Habermann
Consulting or Advisory Role - Celgene; Kite/Gilead
Research Funding - Genentech (Inst)
(OPTIONAL) Uncompensated Relationships - BeiGene; Incyte; Loxo/Lilly; MorphoSys; Seagen; Tessa Therapeutics
 
Stephen M. Ansell
Honoraria - Research to Practice; WebMD
Research Funding - ADC Therapeutics (Inst); Affimed Therapeutics (Inst); AI Therapeutics (Inst); Bristol-Myers Squibb (Inst); Regeneron (Inst); Seagen (Inst); Trillium Therapeutics (Inst)